CAR T-Cell Therapy Market Size, Growth, Share & Trends Analysis
Report Code
PH 9093
Published in
Feb, 2026, By MarketsandMarkets™
CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031
USD 13.78 BN
MARKET SIZE, 2031
CAGR 13.7%
(2026-2031)
280
REPORT PAGES
300
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global CAR T-cell therapy market, valued at USD 6.03 billion in 2025, stood at USD 7.24 billion in 2026 and is projected to advance at a resilient CAGR of 13.7% from 2026 to 2031, culminating in a forecasted valuation of USD 13.78 billion by the end of the period. The global CAR T-cell therapy market is growing due to rapid technological advances alongside rising investments from large pharma and well-funded biotechs. These shifts are improving product consistency, vein-to-vein reliability, and center throughput, and enabling broader clinical adoption, supported by label expansions and earlier-line movement in key hematologic malignancies. However, market scaling is still constrained by high total cost and reimbursement friction.
KEY TAKEAWAYS
-
BY REGIONThe North America CAR T- cell therapy market accounted for a 67.7% revenue share in 2025.
-
BY PRODUCTBy product, the YESCARTA segment is expected to dominate the market, with a share of 25.3% in 2025.
-
BY TARGETBy target, the CD19 segment is expected to dominate the market, with a share of 62.3%.
-
BY INDICATIONBy indication, multiple myeloma dominated the CAR T- cell therapy market.
-
BY DEMOGRAPHICBy demographics, the adult segment is expected to dominate the market.
-
BY END USERBy end user, the hospitals segment is expected to dominate the market.
-
COMPETITIVE LANDSCAPEBristol-Myers Squibb Company (US), Gilead Sciences, Inc. (US), and Novartis AG (Switzerland) were identified as some of the star players in the CAR T-cell therapy market , given their strong market share and product footprint.
-
COMPETITIVE LANDSCAPECRISPR Therapeutics (Switzerland) and Allogene Therapeutics (US), among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global market for CAR T-cell therapy is growing steadily. The primary factors are the increased use of these therapies in relapsed/refractory hematologic cancers and ongoing label expansions. The development of next-gen constructs, dual/multi-target CARs, and allogeneic approaches in the clinical pipeline is progressively enabling the untapped solid tumor patients to be treated. Advanced manufacturing and improved safety and efficacy management are also contributing to stronger real-world adoption. An upsurge in the influx of pharma, biotech, and supportive regulatory pathways enabling investments is global commercialization and access.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
A number of structural changes have been influencing the effects on various stakeholder groups within the global CAR T-cell therapy market. More detailed immune and cancer profiling is becoming the norm in order to help target discovery, patient stratification and prediction of response/toxicity, thus a perfect analytical workflow that is quantitative, robust and can be used for both preclinical and clinical stages is highly demanded. Since CAR-T treatments are expanding and diversifying (dual, target, armored, allogeneic), the reliance on data-driven decision-making has become core of development and commercialization. Hence, more funding is being directed to advanced analytics, biomarker platforms and the development of integrated translational tools that make CAR-T development and deployment faster, safer and more predictable.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Technological advancements in CAR T-cell therapies
-
Label expansions along with strong efficacy signals in hematologic cancers
RESTRAINTS
Impact
Level
Level
-
High cost and reimbursement challenges
OPPORTUNITIES
Impact
Level
Level
-
Expanding beyond hematologic malignancies into solid tumors and new disease areas
-
Focus shift on allogeneic CAR-T and CAR-NK
CHALLENGES
Impact
Level
Level
-
Long-term safety surveillance and evolving labeling requirements
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Technological advancements in CAR T-cell therapies
Growing technological advancements are a major CAR-T market driver because they are steadily converting CAR-T from a 'bespoke, inflexible therapy' into a more repeatable, scalable, and globally deployable platform. On the manufacturing side, the shift toward closed, automated, and semi-automated workflows is reducing manual touchpoints (and contamination risk), improving batch-to-batch consistency, and helping sites run CAR-T with fewer specialized resources. CAR-T manufacturing sites are increasingly adopting automation platforms.
Restraint: High cost and reimbursement challenges
The high cost of CAR T-cell therapy is a significant restraint on market adoption, limiting its accessibility. One of the primary factors in the complex, individualized manufacturing process required for CAR T-cell therapies. Each treatment contributing to the elevated cost involves extracting T cells from the patient, genetically modifying them to express CARs, and expanding them in a controlled laboratory environment before reinfusing them into the patient. This labor-intensive, time-consuming process incurs substantial costs, often exceeding USD 350,000 per treatment, as seen with therapies such as Kymriah and Yescarta.
Opportunity: Expanding beyond hematologic malignancies into solid tumors and new disease areas
While blood cancers remain the core revenue-generating area, the next wave of value lies in solid tumors and potentially non-oncology areas (e.g., autoimmune). Here, patient populations are larger, and chronic-care economics differ. Companies and researchers increasingly see CAR engineering as a route to overcome solid tumor barriers. Each technical breakthrough is expected to open high-volume indications and diversify revenue.
Challenge: Long-term safety surveillance and evolving labeling requirements
A key market challenge is that CAR-T safety oversight is not 'one-and-done.' Regulators have required updates, such as boxed warnings and lifelong monitoring recommendations for secondary malignancies and other serious events, increasing long-term follow-up expectations and operational workload. These requirements can increase delivery complexity for smaller centers, affect outpatient eligibility, and create friction in payer-provider decision-making.
CAR T-CELL THERAPY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
CHOP’s Cancer Immunotherapy Program has been a leading clinical site in advancing CAR-T for pediatric/young adult leukemia, including early investigation of tisagenlecleucel (Kymriah) in collaboration with industry and academic partners. | Faster translation of CAR-T innovations into pediatric care pathways. Strong clinical confidence through deep protocol experience. Improved standardization of monitoring and follow-up in high-risk patients. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global CAR T-cell therapy ecosystem includes an extensive range of stakeholders who support the various stages from discovery, clinical development to commercial manufacturing. This starts with essential raw materials such as viral vectors, cell culture media, activation reagents, gene-editing tools, and single-use manufacturing consumables. These materials are increasingly sourced from global suppliers with local manufacturing and distribution facilities to ensure reliability and scale of supply. The ecosystem further comprises automated cell-processing platforms, analytical and quality-control technologies, and CDMOs that facilitate consistent, and GMP-compliant CAR T production.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
CAR T-Cell Market, by Product
In 2025, Yescarta accounted for a leading share of the global CAR T-cell therapy market, supported by broad adoption in large B-cell lymphoma across major treatment centers and sustained real-world performance confidence. Its scale advantage, built on established referral networks, manufacturing throughput and clinician familiarity, helps maintain strong momentum even as competition intensifies.
CAR T-Cell Market, By target
In 2025, CD19 continued to capture the largest share of the global CAR T-cell therapy market, driven by its broad clinical validation across B-cell malignancies and sustained uptake across major treatment centers. The depth of evidence, established treatment pathways, and continued label expansions in large B-cell lymphoma and related indications reinforce CD19 as the most commercially mature CAR-T target.
CAR T-Cell Market, By indication
In 2025, B-cell lymphomas continued to account for the largest share of the global CAR T-cell therapy market, driven by sustained utilization of CD19-directed CAR-Ts across key lymphoma subtypes and established treatment pathways in major markets.
CAR T-Cell Market, By demographic
In 2025, the adult segment continues to dominate the global CAR T-cell therapy market, reflecting the concentration of eligible patient populations in adult hematologic malignancies and the adult-heavy mix of approved indications. Most commercial CAR-T utilization is anchored in adult lymphoma and multiple myeloma treatment pathways, supported by established referral networks and expanding capacity at certified treatment centers.
CAR T-Cell Market, By end user
Hospitals accounted for the dominant share of the global CAR T-cell therapy market, in 2025. This was mainly because CAR-T administration is concentrated in accredited hospital-based transplant and oncology centers. These settings are essential for managing complex logistics, inpatient infusion and intensive monitoring for acute toxicities such as CRS and neurotoxicity. The need for specialized infrastructure, multidisciplinary care teams and reimbursement alignment continues to anchor CAR-T utilization within hospitals. This reinforces their central role as the primary end users globally.
REGION
Asia Pacific to be the fastest-growing region in the global CAR T-cell market during the forecast period
Biopharma R&D expansion, rapid clinical trial activity growth and increasing investments in advanced cell and gene therapy infrastructure are some of the factors driving Asia Pacific as a high-growth region in the global CAR T-cell therapy market. China, Japan, South Korea and India are consolidating their positions through domestic CAR-T development, local manufacturing, and regulatory pathways supportive of healthcare. The region has a high uptick of automated cell processing platforms, viral vector capabilities and specialized CDMO services usage by the academic institutions and hospitals.
CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX
Among the top-tier global CAR T-cell therapy industry map companies, Bristol Myers Squibb (Star) continues to stand out as a major benchmark player. This is substantiated by a scaled commercial CAR T footprint, profound clinical and real-world evidence generation, and robust manufacturing, quality systems, and global market access capabilities. The company's hematologic indications portfolio and continuous next-generation innovation investments, as well as operational excellence, further bolster its leadership in usage adoption and lifecycle expansion. JW Therapeutics (Emerging Leader) is fast-tracking its position by localizing development and commercialization in China, thus taking advantage of regional regulatory familiarity, an expanding treatment center network, and increasingly robust manufacturing and supply capabilities.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Bristol-Myers Squibb Company (US)
- Johnson & Johnson (US)
- Gilead Sciences, Inc. (US)
- Novartis AG (Switzerland)
- JW (Cayman) Therapeutics Co. Ltd (China)
- ImmunoACT (India)
- CARsgen Therapeutics Holdings Limited (China)
- IASO biotherapeutics (China)
- Autolus Therapeutics (UK)
- Cartesian Therapeutics, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 6.03 Billion |
| Market Forecast in 2031 (Value) | USD 13.78 Billion |
| Growth Rate | CAGR of 13.7% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
WHAT IS IN IT FOR YOU: CAR T-CELL THERAPY MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Regional demand and adoption analysis (US/EU/APAC focus) | Assessed CAR-T adoption by country and indication (DLBCL, MM, ALL), mapped certified treatment centers, referral flows, reimbursement status, and capacity constraints | Enables region-specific launch sequencing, site expansion planning, and realistic revenue ramp-up assumptions |
| Competitive positioning and product landscape | Benchmarked approved and late-stage CAR-T products by target, indication, line of therapy, safety profile, pricing, and manufacturing model (autologous vs allogeneic) | Helps refine differentiation strategy, lifecycle planning, and positioning vs incumbent products |
RECENT DEVELOPMENTS
- May 2024 : The US FDA granted accelerated approval to Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.
- April 2024 : Bristol entered a worldwide capacity reservation and supply agreement with Cellares to manufacture CAR T-cell therapies using Cellares's automated & high-throughput manufacturing platform, Cell Shuttle.
- April 2024 : The European Commission (EC) has approved a Type II variation of Carvykti (ciltacabtagene autoleucel) for treating adult patients with relapsed and refractory multiple myeloma (RRMM). These patients have received at least one prior therapy, such as an immunomodulatory agent (IMiD) or proteasome inhibitor (PI), have shown disease progression during the last treatment, and are resistant to lenalidomide.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
31
2
EXECUTIVE SUMMARY
36
3
PREMIUM INSIGHTS
41
4
MARKET OVERVIEW
Emerging CAR T-cell therapies poised to revolutionize cancer treatment despite cost and safety hurdles.
44
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPIES
4.2.1.2
LABEL EXPANSIONS AND STRONG EFFICACY SIGNALS IN HEMATOLOGIC CANCERS
4.2.1.3
GROWING INVESTMENT IN CAR T-CELL THERAPY DEVELOPMENT
4.2.2
RESTRAINTS
4.2.2.1
HIGH COST AND REIMBURSEMENT CHALLENGES FOR CAR T-CELL THERAPY
4.2.3
OPPORTUNITIES
4.2.3.1
EXPANDING BEYOND HEMATOLOGIC MALIGNANCIES INTO SOLID TUMORS AND NEW DISEASE AREAS
4.2.3.2
FOCUS SHIFT ON ALLOGENEIC CAR-T AND CAR-NK
4.2.3.3
GROWING COLLABORATIONS AMONG BIOPHARMACEUTICAL COMPANIES, ACADEMIC INSTITUTIONS, AND RESEARCH ORGANIZATIONS
4.2.4
CHALLENGES
4.2.4.1
LONG-TERM SAFETY SURVEILLANCE AND EVOLVING LABELING REQUIREMENTS
4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.6
PIPELINE ANALYSIS
5
INDUSTRY TRENDS
Navigate competitive pressures and pricing shifts in the evolving global CAR-T-cell therapy landscape.
55
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
BARGAINING POWER OF SUPPLIERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECASTS
5.2.3
TRENDS IN GLOBAL CAR-T-CELL THERAPY MARKET
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.4.1
ROLE IN ECOSYSTEM
5.5
PRICING ANALYSIS
5.5.1
AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY TYPE, 2025
5.5.2
AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY KEY PLAYER, 2025
5.5.3
AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY REGION, 2025
5.6
KEY CONFERENCES & EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.8
INVESTMENT/FUNDING SCENARIO
5.9
IMPACT OF 2025 US TARIFF ON CAR T-CELL THERAPY MARKET
5.9.1
KEY TARIFF RATES
5.9.2
PRICE IMPACT ANALYSIS
5.9.3
IMPACT ON COUNTRY/REGION
5.9.3.1
NORTH AMERICA
5.9.3.1.1
US
5.9.3.2
EUROPE
5.9.3.3
ASIA PACIFIC
5.9.4
IMPACT ON END-USE INDUSTRIES
5.9.4.1
HOSPITALS
5.9.4.2
SPECIALTY ONCOLOGY CENTERS
5.9.4.3
LONG-TERM CARE FACILITIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize CAR T-cell therapy with cutting-edge gene editing and imaging technologies.
72
6.1
TECHNOLOGY ANALYSIS
6.1.1
KEY TECHNOLOGIES
6.1.1.1
CAR DESIGN AND OPTIMIZATION
6.1.1.2
VIRAL VECTOR TECHNOLOGY
6.1.1.3
CELL CULTURE AND EXPANSION TECHNIQUES
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
GENE EDITING TECHNOLOGY (CRISPR-CAS9-BASED GENOME EDITING)
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
MONITORING AND IMAGING TECHNOLOGIES
6.2
TECHNOLOGY/PRODUCT ROADMAP
6.3
FUTURE APPLICATIONS
6.4
IMPACT OF AI/GEN AI ON CAR T-CELL THERAPY MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
Navigate complex global regulations to leverage eco-standards and optimize CAR T-cell therapy compliance.
77
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
REGULATORY FRAMEWORK
7.1.3
INDUSTRY STANDARDS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
7.4
REIMBURSEMENT SCENARIO
7.5
COMBINATION THERAPIES
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Unlocking buyer insights: Navigate stakeholder dynamics and unmet needs to boost market profitability.
86
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
KEY BUYING CRITERIA, BY END USER
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5
MARKET PROFITABILITY
9
CAR T-CELL THERAPY MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 51 Data Tables
90
9.1
INTRODUCTION
9.2
ABECMA
9.2.1
FOCUS ON INCREASED RESEARCH ACTIVITIES FOR INDICATION EXPANSIONS TO DRIVE MARKET
9.3
BREYANZI
9.3.1
NEED FOR TREATMENT OF MULTIPLE INDICATIONS TO PROPEL MARKET GROWTH
9.4
CARVYKTI
9.4.1
GLOBAL REACH AND SIGNIFICANT REVENUE GROWTH TO SUPPORT MARKET
9.5
YESCARTA
9.5.1
FOCUS ON REGULATORY APPROVALS ACROSS MAJOR REGIONS TO BOOST MARKET GROWTH
9.6
TECARTUS
9.6.1
EFFORTS TO SECURE REIMBURSEMENT AND IMPROVE MARKET ACCESS FACILITATE PATIENT TO AID MARKET ADOPTION
9.7
KYMRIAH
9.7.1
APPROVAL FOR PEDIATRIC USE TO AUGMENT MARKET GROWTH
9.8
OTHER PRODUCTS
10
CAR T-CELL THERAPY MARKET, BY TARGET
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 38 Data Tables
117
10.1
INTRODUCTION
10.2
CD19
10.2.1
RISING INDICATION EXPANSIONS AND NEW APPROVALS TO DRIVE MARKET
10.3
BCMA
10.3.1
GROWING PIPELINE PRODUCTS TO PROPEL MARKET GROWTH
10.4
CD19/20
10.4.1
DUAL TARGETING TO OFFER COMPETITIVE ADVANTAGE IN ANTIGEN ESCAPE AND TUMOR HETEROGENEITY ISSUES
10.5
CD7
10.5.1
ALLOGENEIC CELL SOURCE OF CD7 THERAPIES IN DEVELOPMENT TO SUPPORT GROWTH
10.6
OTHER TARGETS
11
CAR T-CELL THERAPY MARKET, BY INDICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
136
11.1
INTRODUCTION
11.2
B-CELL LYMPHOMA (BCL)
11.2.1
RISING PREVALENCE OF B-CELL LYMPHOMAS TO PROPEL MARKET GROWTH
11.3
MULTIPLE MYELOMA
11.3.1
GROWING PRODUCT REVENUE AND RISING GLOBAL INCIDENCE OF MYELOMA TO DRIVE MARKET
11.4
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
11.4.1
EXPANDING R&D PIPELINE TO AUGMENT MARKET GROWTH
11.5
OTHER INDICATIONS
12
CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 15 Data Tables
152
12.1
INTRODUCTION
12.2
ADULTS
12.2.1
GROWING PREVALENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET
12.3
PEDIATRIC
12.3.1
HIGH UNMET NEEDS TO LIMIT SEGMENT GROWTH
13
CAR T-CELL THERAPY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
160
13.1
INTRODUCTION
13.2
HOSPITALS
13.2.1
GROWING NEED FOR STANDARD ONCOLOGY TREATMENT PROTOCOLS TO DRIVE MARKET
13.3
SPECIALTY CENTRES
13.3.1
NEED FOR OPTIMAL PATIENT CARE AND SPECIALIZED TREATMENT OPTIONS TO SPUR MARKET GROWTH
13.4
LONG-TERM CARE FACILITIES
13.4.1
INCREASING INCIDENCE OF CHRONIC DISORDERS AMONG GERIATRIC POPULATION TO PROPEL MARKET GROWTH
14
CAR T-CELL THERAPY MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 15 Countries | 137 Data Tables.
172
14.1
INTRODUCTION
14.2
NORTH AMERICA
14.2.1
US
14.2.1.1
US TO DOMINATE CAR T-CELL THERAPY MARKET DURING STUDY PERIOD
14.2.2
CANADA
14.2.2.1
REGULATORY APPROVALS AND GOVERNMENT INITIATIVES FOR REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET
14.3
EUROPE
14.3.1
GERMANY
14.3.1.1
KEY PRODUCT APPROVALS AND FOCUS ON CLINICAL RESEARCH TO AID MARKET GROWTH
14.3.2
UK
14.3.2.1
TECHNOLOGICAL ADVANCEMENTS IN AUTOMATION AND PRESENCE OF ROBUST RESEARCH INFRASTRUCTURE TO SPUR MARKET GROWTH
14.3.3
FRANCE
14.3.3.1
GROWING FOCUS ON CELL & GENE THERAPY INITIATIVES TO BOOST MARKET GROWTH
14.3.4
ITALY
14.3.4.1
GROWTH IN BIOTECH SECTOR TO AUGMENT MARKET GROWTH
14.3.5
SPAIN
14.3.5.1
RISING FOCUS ON CELL THERAPIES AND GROWING FOCUS ON STRINGENT REGULATIONS TO AUGMENT MARKET GROWTH
14.3.6
REST OF EUROPE
14.4
ASIA PACIFIC
14.4.1
CHINA
14.4.1.1
RISING NUMBER OF CAR T-CELL CLINICAL TRIALS TO FUEL MARKET GROWTH
14.4.2
JAPAN
14.4.2.1
INCREASING NUMBER OF PRODUCT APPROVALS AND RISING GERIATRIC POPULATION TO PROPEL MARKET GROWTH
14.4.3
INDIA
14.4.3.1
GROWING FOCUS ON PRODUCT COMMERCIALIZATION AND RISING CANCER INCIDENCE TO BOOST MARKET DEMAND
14.4.4
AUSTRALIA
14.4.4.1
ROBUST INFRASTRUCTURE FOR CLINICAL TRIALS AND WELL-DEVELOPED HEALTHCARE SECTOR TO AID MARKET GROWTH
14.4.5
SOUTH KOREA
14.4.5.1
GROWTH IN BIOPHARMACEUTICAL INDUSTRY TO FACILITATE MARKET GROWTH
14.4.6
REST OF ASIA PACIFIC
14.5
LATIN AMERICA
14.5.1
BRAZIL
14.5.1.1
PRODUCT APPROVALS AND HIGH HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH
14.5.2
REST OF LATIN AMERICA
14.6
MIDDLE EAST
14.6.1
GCC COUNTRIES
14.6.2
KINGDOM OF SAUDI ARABIA
14.6.2.1
INCREASED NUMBER OF PRODUCT APPROVALS AND HIGH HEALTHCARE EXPENDITURE TO BOOST MARKET GROWTH
14.6.3
UAE
14.6.3.1
UAE MARKET GROWTH TO BE DRIVEN BY LOCALIZED MANUFACTURING, EXPANDED CLINICAL APPLICATIONS, AND STRATEGIC COLLABORATIONS
14.6.4
REST OF MIDDLE EAST
14.7
AFRICA
14.7.1
SIGNIFICANT BURDEN OF HEMATOLOGIC MALIGNANCIES AND INFECTIOUS DISEASES TO PROPEL MARKET GROWTH
15
COMPETITIVE LANDSCAPE
Discover strategic insights and market positioning of key players in CAR T-cell therapy.
235
15.1
INTRODUCTION
15.2
KEY PLAYER STRATEGY/RIGHT TO WIN
15.2.1
OVERVIEW OF MAJOR STRATEGIES ADOPTED BY PLAYERS IN CAR T-CELL THERAPY MARKET
15.3
REVENUE ANALYSIS, 2023–2025
15.4
MARKET SHARE ANALYSIS, 2025
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1
STARS
15.5.2
EMERGING LEADERS
15.5.3
PERVASIVE PLAYERS
15.5.4
PARTICIPANTS
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
REGION FOOTPRINT
15.5.5.3
PRODUCT FOOTPRINT
15.5.5.4
TARGET FOOTPRINT
15.5.5.5
INDICATION FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.3
DYNAMIC COMPANIES
15.6.4
STARTING BLOCKS
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
15.7
COMPANY VALUATION & FINANCIAL METRICS
15.7.1
FINANCIAL METRICS
15.7.2
COMPANY VALUATION
15.8
BRAND/PRODUCT COMPARISON
15.9
COMPETITIVE SCENARIO
15.9.1
PRODUCT APPROVALS
15.9.2
DEALS
15.9.3
EXPANSIONS
15.9.4
OTHER DEVELOPMENTS
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
255
16.1
KEY PLAYERS
16.1.1
JOHNSON & JOHNSON
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.3.1
PRODUCT APPROVALS
16.1.1.3.2
DEALS
16.1.1.4
MNM VIEW
16.1.1.4.1
KEY STRENGTHS
16.1.1.4.2
STRATEGIC CHOICES
16.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
16.1.2
GILEAD SCIENCES, INC.
16.1.3
BRISTOL-MYERS SQUIBB COMPANY
16.1.4
NOVARTIS AG
16.1.5
AUTOLUS THERAPEUTICS
16.1.6
JW (CAYMAN) THERAPEUTICS CO., LTD.
16.1.7
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
16.1.8
CARSGEN THERAPEUTICS HOLDINGS LIMITED
16.1.9
IASO BIOTHERAPEUTICS
16.1.10
IMMUNEEL THERAPEUTICS
16.2
OTHER PLAYERS
16.2.1
WUGEN
16.2.2
CARTESIAN THERAPEUTICS, INC.
16.2.3
ALLOGENE THERAPEUTICS
16.2.4
LYELL IMMUNOPHARMA, INC.
16.2.5
KYVERNA THERAPEUTICS, INC.
16.2.6
CELLICTIS SA
16.2.7
BRAINCHILD BIO
16.2.8
ATARA BIOTHERAPEUTICS, INC.
16.2.9
CARIBOU BIOSCIENCES
16.2.10
ARCELLX
16.2.11
CRISPR THERAPEUTICS
16.2.12
POSEIDA THERAPEUTICS
16.2.13
CABALETTA BIO
17
RESEARCH METHODOLOGY
299
17.1
RESEARCH DATA
17.1.1
SECONDARY DATA
17.1.1.1
OBJECTIVES OF SECONDARY RESEARCH
17.1.2
PRIMARY DATA
17.1.2.1
BREAKDOWN OF PRIMARIES
17.1.2.2
OBJECTIVES OF PRIMARY RESEARCH
17.2
MARKET SIZE ESTIMATION
17.2.1
BOTTOM-UP APPROACH
17.2.2
INSIGHTS FROM PRIMARY EXPERTS
17.2.3
SEGMENTAL MARKET SIZE ESTIMATION
17.3
GROWTH RATE ASSUMPTIONS
17.3.1
CAGR PROJECTIONS
17.3.2
IMPACT OF SUPPLY- AND DEMAND-SIDE FACTORS
17.4
DATA TRIANGULATION
17.5
RESEARCH LIMITATIONS
17.6
STUDY ASSUMPTIONS
17.7
RISK ANALYSIS
18
APPENDIX
312
18.1
DISCUSSION GUIDE
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.4
RELATED REPORTS
18.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
CAR T-CELL THERAPY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
KEY PIPELINE PRODUCTS IN PHASE-2 AND PHASE-3 CAR T-CELL THERAPY MARKET (AS OF 2025)
TABLE 3
IMPACT OF PORTER’S FIVE FORCES ON CAR T-CELL THERAPY MARKET
TABLE 4
ROLE OF MAJOR COMPANIES IN CAR T-CELL THERAPY MARKET ECOSYSTEM (SUPPLY AND DEMAND SIDES)
TABLE 5
AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY TYPE, 2025 (USD)
TABLE 6
AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY REGION, 2025
TABLE 7
KEY CONFERENCES & EVENTS IN CAR T-CELL THERAPY MARKET, JANUARY 2026–DECEMBER 2027
TABLE 8
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 9
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
COUNTRY-WISE REGULATORY SCENARIO FOR CAR T-CELL THERAPY PRODUCT MANUFACTURERS
TABLE 14
CAR T-CELL THERAPY MARKET: REIMBURSEMENT STATUS AND FUNDING CHANNEL, BY COUNTRY/REGION (AS OF 2026)
TABLE 15
CAR T-CELL THERAPY MARKET: HCPCS CODES OF COMMERCIALIZED THERAPIES
TABLE 16
COMBINATION THERAPY TRIALS IN CAR T-CELL THERAPY MARKET
TABLE 17
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%)
TABLE 18
KEY BUYING CRITERIA, BY END USER
TABLE 19
CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 20
CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (NUMBER OF THERAPIES)
TABLE 21
CAR T-CELL THERAPY MARKET FOR ABECMA, BY REGION, 2024–2031 (USD MILLION)
TABLE 22
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23
EUROPE: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 24
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 26
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 27
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR ABECMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28
CAR T-CELL THERAPY MARKET FOR BREYANZI, BY REGION, 2024–2031 (USD MILLION)
TABLE 29
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30
EUROPE: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR BREYANZI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY REGION, 2024–2031 (USD MILLION)
TABLE 36
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
EUROPE: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR CARVYKTI, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
CAR T-CELL THERAPY MARKET FOR YESCARTA, BY REGION, 2024–2031 (USD MILLION)
TABLE 43
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
EUROPE: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR YESCARTA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
CAR T-CELL THERAPY MARKET FOR TECARTUS, BY REGION, 2024–2031 (USD MILLION)
TABLE 50
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
EUROPE: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR TECARTUS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY REGION, 2024–2031 (USD MILLION)
TABLE 57
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
EUROPE: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR KYMRIAH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 64
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 71
COMMERCIALLY AVAILABLE CD19 ANTIGEN TARGETING CAR T-CELL THERAPIES
TABLE 72
CD19-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 73
NORTH AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74
EUROPE: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
ASIA PACIFIC: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76
LATIN AMERICA: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
MIDDLE EAST: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
GCC COUNTRIES: CD19-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
COMMERCIALLY AVAILABLE BCMA ANTIGEN TARGETING CAR T-CELL THERAPIES
TABLE 80
BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 81
NORTH AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
EUROPE: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83
ASIA PACIFIC: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84
LATIN AMERICA: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85
MIDDLE EAST: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
GCC COUNTRIES: BCMA-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 88
NORTH AMERICA: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89
EUROPE: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90
ASIA PACIFIC: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91
LATIN AMERICA: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
MIDDLE EAST: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
GCC COUNTRIES: CD19/20-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
CD7-TARGETING CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 95
NORTH AMERICA: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96
EUROPE: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97
ASIA PACIFIC: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98
LATIN AMERICA: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99
MIDDLE EAST: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
GCC COUNTRIES: CD7-TARGETING CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
OTHER CAR T-CELL THERAPY TARGETS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 102
NORTH AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103
EUROPE: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104
ASIA PACIFIC: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105
LATIN AMERICA: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106
MIDDLE EAST: OTHER CAR T-CELL THERAPY TARGETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107
GCC COUNTRIES: OTHER CAR T-CELL THERAPY TARGETS MARKETA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 109
CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY REGION, 2024–2031 (USD MILLION)
TABLE 110
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111
EUROPE: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR B-CELL LYMPHOMA (BCL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116
CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY REGION, 2024–2031(USD MILLION)
TABLE 117
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 118
EUROPE: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 119
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 120
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR MULTIPLE MYELLOMA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123
CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2024–2031(USD MILLION)
TABLE 124
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031(USD MILLION)
TABLE 125
EUROPE: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031(USD MILLION)
TABLE 126
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031(USD MILLION)
TABLE 127
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130
CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 131
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132
EUROPE: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137
CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 138
CAR T-CELL THERAPY MARKET FOR ADULTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 139
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
EUROPE: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR ADULTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145
CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY REGION, 2024–2031 (USD MILLION)
TABLE 146
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147
EUROPE: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 151
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR PEDIATRIC, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 152
CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 153
CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 154
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155
EUROPE: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 157
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 160
CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY REGION, 2024–2031 (USD MILLION)
TABLE 161
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162
EUROPE: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 166
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR SPECIALTY CENTRES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 167
CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2031(USD MILLION)
TABLE 168
NORTH AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 169
EUROPE: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 170
ASIA PACIFIC: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 171
LATIN AMERICA: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 172
MIDDLE EAST: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 173
GCC COUNTRIES: CAR T-CELL THERAPY MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2031(USD MILLION)
TABLE 174
CAR T-CELL THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 175
NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 177
NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 178
NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 179
NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 180
NORTH AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 181
US: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 182
US: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 183
US: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 184
US: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 185
US: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 186
CANADA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 187
CANADA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 188
CANADA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 189
CANADA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 190
CANADA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 191
EUROPE: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192
EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 193
EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 194
EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 195
EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 196
EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 197
GERMANY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 198
GERMANY: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 199
GERMANY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 200
GERMANY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 201
GERMANY: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 202
UK: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 203
UK: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 204
UK: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 205
UK: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 206
UK: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 207
FRANCE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 208
FRANCE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 209
FRANCE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 210
FRANCE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 211
FRANCE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 212
ITALY: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 213
ITALY: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 214
ITALY: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 215
ITALY: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 216
ITALY: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 217
SPAIN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 218
SPAIN: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 219
SPAIN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 220
SPAIN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 221
SPAIN: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 222
REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 223
REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 224
REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 225
REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 226
REST OF EUROPE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 227
ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228
ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 229
ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 230
ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 231
ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 232
ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 233
CHINA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 234
CHINA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 235
CHINA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 236
CHINA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 237
CHINA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 238
JAPAN: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 239
JAPAN: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 240
JAPAN: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 241
JAPAN: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 242
JAPAN: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 243
INDIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 244
INDIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 245
INDIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 246
INDIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 247
INDIA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 248
AUSTRALIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 249
AUSTRALIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 250
AUSTRALIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 251
AUSTRALIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 252
AUSTRALIA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 253
SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 254
SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 255
SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 256
SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 257
SOUTH KOREA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 258
REST OF ASIA PACIFC: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 259
REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 260
REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 261
REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 262
REST OF ASIA PACIFIC: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 263
LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264
LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 265
LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 266
LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 267
LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 268
LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 269
BRAZIL: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 270
BRAZIL: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 271
BRAZIL: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 272
BRAZIL: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 273
BRAZIL: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 274
REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 275
REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 276
REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 277
REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 278
REST OF LATIN AMERICA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 279
MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 280
MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 281
MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 282
MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 283
MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 284
MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 285
GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 286
GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 287
GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 288
GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 289
GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 290
GCC COUNTRIES: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 291
KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 292
KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 293
KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 294
KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 295
KINGDOM OF SAUDI ARABIA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 296
UAE: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 297
UAE: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 298
UAE: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 299
UAE: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 300
UAE: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 301
REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 302
REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 303
REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 304
REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 305
REST OF MIDDLE EAST: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 306
AFRICA: CAR T-CELL THERAPY MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 307
AFRICA: CAR T-CELL THERAPY MARKET, BY TARGET, 2024–2031 (USD MILLION)
TABLE 308
AFRICA: CAR T-CELL THERAPY MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 309
AFRICA: CAR T-CELL THERAPY MARKET, BY DEMOGRAPHIC, 2024–2031 (USD MILLION)
TABLE 310
AFRICA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 311
OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CAR T-CELL THERAPY MARKET
TABLE 312
CAR T-CELL THERAPY MARKET: DEGREE OF COMPETITION
TABLE 313
CAR T-CELL THERAPY MARKET: REGION FOOTPRINT
TABLE 314
CAR T-CELL THERAPY MARKET: PRODUCT FOOTPRINT
TABLE 315
CAR T-CELL THERAPY MARKET: TARGET FOOTPRINT
TABLE 316
CAR T-CELL THERAPY MARKET: INDICATION FOOTPRINT
TABLE 317
CAR T-CELL THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 318
CAR T-CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY DEMOGRAPHY AND REGION, 2025
TABLE 319
CAR T-CELL THERAPY MARKET: PRODUCT APPROVALS, JANUARY 2022–JANUARY 2026
TABLE 320
CAR T-CELL THERAPY MARKET: DEALS, JANUARY 2022–JANUARY 2026
TABLE 321
CAR T-CELL THERAPY MARKET: EXPANSIONS, JANUARY 2022–JANUARY 2026
TABLE 322
CAR T-CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2026
TABLE 323
JOHNSON & JOHNSON: COMPANY OVERVIEW
TABLE 324
JOHNSON & JOHNSON: PRODUCTS OFFERED
TABLE 325
JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026
TABLE 326
JOHNSON & JOHNSON: DEALS, JANUARY 2022−JANUARY 2026
TABLE 327
GILEAD SCIENCES, INC.: COMPANY OVERVIEW
TABLE 328
GILEAD SCIENCES, INC.: PRODUCTS OFFERED
TABLE 329
GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2022–JANUARY 2026
TABLE 330
GILEAD SCIENCES, INC.: DEALS, JANUARY 2022–JANUARY 2026
TABLE 331
GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2026
TABLE 332
BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
TABLE 333
BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
TABLE 334
BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2022–JANUARY 2026
TABLE 335
BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2022–JANUARY 2026
TABLE 336
NOVARTIS AG: COMPANY OVERVIEW
TABLE 337
NOVARTIS AG: PRODUCTS OFFERED
TABLE 338
NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026
TABLE 339
NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2022−JANUARY 2026
TABLE 340
AUTOLUS THERAPEUTICS: COMPANY OVERVIEW
TABLE 341
AUTOLUS THERAPEUTICS: PRODUCTS OFFERED
TABLE 342
AUTOLUS THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026
TABLE 343
AUTOLUS THERAPEUTICS: DEALS, JANUARY 2022−JANUARY 2026
TABLE 344
JW (CAYMAN) THERAPEUTICS CO., LTD.: COMPANY OVERVIEW
TABLE 345
JW (CAYMAN) THERAPEUTICS CO., LTD.: PRODUCTS OFFERED
TABLE 346
JW (CAYMAN) THERAPEUTICS CO., LTD.: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026
TABLE 347
JW (CAYMAN) THERAPEUTICS CO., LTD.: DEALS, JANUARY 2022−JANUARY 2026
TABLE 348
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT): COMPANY OVERVIEW
TABLE 349
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT): PRODUCTS OFFERED
TABLE 350
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT): DEALS, JANUARY 2022−JANUARY 2026
TABLE 351
IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT): OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2026
TABLE 352
CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
TABLE 353
CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED
TABLE 354
CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026
TABLE 355
CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS, JANUARY 2022−JANUARY 2026
TABLE 356
CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS, JANUARY 2022−JANUARY 2026
TABLE 357
IASO BIOTHERAPEUTICS: COMPANY OVERVIEW
TABLE 358
IASO BIOTHERAPEUTICS: PRODUCTS OFFERED
TABLE 359
IASO BIOTHERAPEUTICS: PRODUCT APPROVALS, JANUARY 2022−JANUARY 2026
TABLE 360
IASO BIOTHERAPEUTICS: DEALS, JANUARY 2022−JANUARY 2026
TABLE 361
IMMUNEEL THERAPEUTICS: COMPANY OVERVIEW
TABLE 362
IMMUNEEL THERAPEUTICS: PRODUCTS OFFERED
TABLE 363
IMMUNEEL THERAPEUTICS: PRODUCT LAUNCHES, JANUARY 2022−JANUARY 2026
TABLE 364
WUGEN: COMPANY OVERVIEW
TABLE 365
CARTESIAN THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 366
ALLOGENE THERAPEUTICS: COMPANY OVERVIEW
TABLE 367
LYELL IMMUNOPHARMA, INC.: COMPANY OVERVIEW
TABLE 368
KYVERNA THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 369
CELLICTIS SA: COMPANY OVERVIEW
TABLE 370
BRAINCHILD BIO: COMPANY OVERVIEW
TABLE 371
ATARA BIOTHERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 372
CARIBOU BIOSCIENCES: COMPANY OVERVIEW
TABLE 373
ARCELLX: COMPANY OVERVIEW
TABLE 374
CRISPR THERAPEUTICS: COMPANY OVERVIEW
TABLE 375
POSEIDA THERAPEUTICS: COMPANY OVERVIEW
TABLE 376
CABALETTA BIO: COMPANY OVERVIEW
TABLE 377
IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS ON CAR T-CELL THERAPY MARKET
TABLE 378
CAR T-CELL THERAPY MARKET: RISK ANALYSIS
LIST OF FIGURES
FIGURE 1
CAR T-CELL THERAPY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
CAR T-CELL THERAPY MARKET: YEARS CONSIDERED
FIGURE 3
CAR T-CELL THERAPY MARKET SCENARIO
FIGURE 4
GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2024–2031 (USD MILLION)
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CAR T-CELL THERAPY MARKET, 2023–2025
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF CAR T-CELL THERAPY MARKET
FIGURE 7
HIGH-GROWTH SEGMENTS IN CAR T-CELL THERAPY MARKET, BY PRODUCT, TARGET, END USER, AND REGION, 2026–2031
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CAR T-CELL THERAPY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9
TECHNOLOGICAL ADVANCEMENTS IN CAR T-CELL THERAPIES TO DRIVE GROWTH
FIGURE 10
US AND ADULTS DOMINATED NORTH AMERICAN CAR T-CELL THERAPY MARKET IN 2025
FIGURE 11
INDIA TO REGISTER FASTEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 12
CAR T-CELL THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13
GLOBAL CAR T-CELL THERAPY TRIALS DISTRIBUTION, BY TARGET (ACROSS ALL PHASES OF DEVELOPMENT), 2025
FIGURE 14
GLOBAL CAR T-CELL THERAPY TRIALS DISTRIBUTION OF TARGET BY DEVELOPMENT PHASE, 2025
FIGURE 15
CAR T-CELL THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16
CAR T-CELL THERAPY MARKET: VALUE CHAIN ANALYSIS
FIGURE 17
CAR T-CELL THERAPY MARKET: ECOSYSTEM ANALYSIS
FIGURE 18
AVERAGE SELLING PRICE OF CAR T-CELL THERAPY PRODUCTS, BY KEY PLAYER, 2025 (USD)
FIGURE 19
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN CAR T-CELL THERAPY MARKET
FIGURE 20
FUNDING AND NUMBER OF DEALS IN CAR T-CELL THERAPY MARKET (USD MILLION)
FIGURE 21
IMPACT OF AI/GEN AI ON CAR T-CELL THERAPY MARKET
FIGURE 22
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 23
KEY BUYING CRITERIA FOR MAJOR END USERS
FIGURE 24
NORTH AMERICA: CAR T-CELL THERAPY MARKET SNAPSHOT
FIGURE 25
ASIA PACIFIC: CAR T-CELL THERAPY MARKET SNAPSHOT
FIGURE 26
REVENUE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET, 2023–2025 (USD MILLION)
FIGURE 27
MARKET SHARE ANALYSIS OF KEY PLAYERS IN CAR T-CELL THERAPY MARKET (2025)
FIGURE 28
CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 29
CAR T-CELL MARKET: COMPANY FOOTPRINT
FIGURE 30
CAR T-CELL THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 31
EV/EBITDA OF KEY VENDORS
FIGURE 32
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33
CAR T-CELL THERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 34
JOHNSON & JOHNSON: COMPANY SNAPSHOT
FIGURE 35
GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
FIGURE 36
BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
FIGURE 37
NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 38
JW (CAYMAN) THERAPEUTICS CO., LTD.: COMPANY SNAPSHOT
FIGURE 39
CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY SNAPSHOT
FIGURE 40
CAR T-CELL THERAPY MARKET: RESEARCH DESIGN
FIGURE 41
CAR T-CELL THERAPY MARKET: BREAKDOWN OF DEMAND– AND SUPPLY-SIDE PRIMARIES
FIGURE 42
CAR T-CELL THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
FIGURE 43
CAR T-CELL THERAPY MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2025
FIGURE 44
ILLUSTRATIVE EXAMPLE OF GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS (2025)
FIGURE 45
CAR T-CELL THERAPY MARKET VALIDATION FROM PRIMARY SOURCES
FIGURE 46
CAR T-CELL THERAPY MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 47
CAR T-CELL THERAPY MARKET: CAGR PROJECTIONS, 2026–2031
FIGURE 48
CAR T-CELL THERAPY MARKET: DATA TRIANGULATION METHODOLOGY
Methodology
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the CAR T-Cell Therapy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in CAR T-Cell Therapy Market